JAX Tech Talk Episode 48: Developing Immunotherapies with Hu-NSG-MHC I/II DKO Mice (Jan. 11, 2022)
January 11, 2022 - The NSG-MHC I/II DKO mouse model has the features of the severe combined immune deficiency mutation (scid), IL2 receptor gamma chain deficiency, MHC class I molecule deficiency (H2-K and D), and MHC class II molecule deficiency (IA). Due to the deficiency of murine MHC class I and class II molecules, this model demonstrates significantly delayed onset of GvHD when transplanted with pre-characterized human PBMCs.
In this episode, we will discuss using PBMC humanized NSG-MHC I/II DKO mice in preclinical research to develop and assess efficacy of human immuno-therapeutics.
NSG-MHC I/II DKO Stain Datasheet
FASEB Journal Publication: A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic-related cytokine release syndrome